🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

522 results for “therapy” Clear

  1. SAKK 66/22: Intratumoral INT230-6 followed by neoadjuvant immuno-chemotherapy in patients with early triple-negative breast cancer (TNBC). An open-label randomized two-cohort phase 2 clinical trial. INVINCIBLE-4-SAKK

    The George Institute

    Early triple-negative breast cancer (TNBC)

    phase 2 other active

    1 trial

  2. SBRT combined with PD-1 inhibitors and thoracic hyperthermia

    The First People's Hospital of Lianyungang

    Stereotactic Body Radiation Therapy; PD-1 Inhibitor; Hyperthermia; NSCLC

    phase 2 other active

    1 trial

  3. SKB103 for injection monotherapy

    Sichuan Provincial People's Hospital

    Advanced Solid Tumors

    phase 2 small molecule active

    1 trial

  4. SOX Chemotherapy

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Gastroesophageal Junction Adenocarcinoma

    phase 2 small molecule active

    1 trial

  5. SSS06

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Chemotherapy-induced Anemia

    phase 2 small molecule active

    1 trial

  6. Safety and efficacy of IMM-101 combined with stereotactic radiotherapy in patients with limited metastatic pancreatic cancer (MEPANC-1)

    Disc Medicine

    Limited metastatic pancreatic cancer

    phase 2 other active

    1 trial

  7. Selpercatinib Monotherapy

    United Therapeutics Europe Ltd

    Differentiated Thyroid Cancer

    phase 2 small molecule active

    1 trial

  8. Sintilimab Combined with Platinum-containing Chemotherapy

    The First People's Hospital of Lianyungang

    Non-small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  9. Sintilimab in combination with Multimodality Radiotherapy

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Nasopharyngeal Carcinoma

    phase 2 small molecule active

    1 trial

  10. Sonodynamic therapy(SDT)

    The First People's Hospital of Lianyungang

    Peripheral Arterial Disease

    phase 2 other terminated

    1 trial

  11. Study evaluating the efficacy of the treatment after targeting PD-L1 and TIGIT in tumors with tertiary lymphoid structures

    The George Institute

    Adult patients with a histologically confirmed TLS-positive advanced or metastatic NSCLC naïve from systemic treatment or previously treated with chemotherapy and PD1/PDL1 antagonist, and not having previously been treated with CD137 agonists or investigational immune checkpoint blockade therapies, including (but not limited) anti-TIGIT, anti-LAG3. Patients must have adequate organ function with a performance status (WHO 0-1; ECOG 0-1). Patients must not have active or history of autoimmune disease or immune deficiency. The pregnant or breastfeeding women will be excluded. Other eligibility criteria are described in the related section of the protocol.

    phase 2 other active

    1 trial

  12. Systemic chemotherapy (FOLFIRI)

    The First People's Hospital of Lianyungang

    Rectum Cancer

    phase 2 small molecule completed

    1 trial

  13. TEMOZOLOMIDE , IRINOTECAN

    Fondazione Telethon ETS

    Stage II (pT4)/III colorectal cancer with positive circulating tumor DNA (ctDNA) after oxaliplatin-based adjuvant chemotherapy

    phase 2 small molecule active

    1 trial

  14. TPC induction chemotherapy

    Sun Yat-sen University

    Nasopharyngeal Carcinoma

    phase 2 small molecule active

    1 trial

  15. TRASTUZUMAB, TRASTUZUMAB, TRASTUZUMAB EMTANSINE, TRASTUZUMAB, TRASTUZUMAB DERUXTECAN, PERTUZUMAB, TRASTUZUMAB EMTANSINE

    Ningbo Cancer Hospital

    Patients with HER2-positive locally advanced inoperable or metastatic breast cancer with disease controlled after 2 years of maintenance treatment with anti-HER2 targeted therapy

    phase 2 small molecule active

    1 trial

  16. Tevimbra 100 mg concentrate for solution for infusion

    Ningbo Cancer Hospital

    Patients with Hepatocellular Carcinoma (HCC) and Child-Pugh B, ALBI grade 1 or 2 liver function, pretreated or not by tyrosine kinase inhibitors and not pretreated with immunotherapy.

    phase 2 small molecule active

    1 trial

  17. The treatment group using pembrolizumab combined with anlotinib and radiotherapy and chemotherapy

    The First People's Hospital of Lianyungang

    Esophageal Cancer

    phase 2 small molecule active

    1 trial

  18. Tislelizumab combined with chemoradiotherapy

    The First People's Hospital of Lianyungang

    ESCC

    phase 2 small molecule active

    1 trial

  19. Tislelizumab combined with chemotherapy

    The First People's Hospital of Lianyungang

    Rectal Cancer

    phase 2 small molecule active

    1 trial

  20. Tolinapant, Tolinapant

    Taiho Pharma Netherlands B.V.

    Advanced Solid Tumors and Lymphomas that are metastatic or unresectable: Cohort#1:Recurrent/metastatic head and neck squamous cell carcinoma; #2:Relapsed/refractory diffuse large B-cell lymphoma; #3:Progressive, refractory or relapsed peripheral T-cell lymphoma; #4:Relapsed/refractory cutaneous T-cell lymphoma; #5: Other tumor types that may have sensitivity to ASTX660; # 6: Cervical carcinoma not responsive/relapsed after standard therapy

    phase 2 small molecule active

    1 trial

  21. Toripalimab

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Neoadjuvant Therapy

    phase 2 small molecule active

    1 trial

  22. Toripalimab + Chemotherapy

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Thymic Epithelial Tumor

    phase 2 small molecule active

    1 trial

  23. Toripalimab + Chemotherapy

    Coherus Oncology

    Head and Neck Cancer

    phase 2 small molecule active

    1 trial

  24. VX-522 mRNA therapy

    Vertex Pharmaceuticals (Australia) Pty.

    Cystic Fibrosis

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources